Eribulin mesylate injection: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Eribulin mesylate injection

• A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
  NCT06202261 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
  NCT06079983 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 87 locations
• Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
  NCT06255392 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many recruiting trials involve Eribulin mesylate injection?

3 recruiting trials across 6 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.